Ganesh Moorthy

Ganesh Moorthy

AstraZeneca, Sweden - Södertälje / Sweden
Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences
AD Scientific Index ID: 4532914
-
person_outline Ganesh Moorthy's MOST POPULAR ARTICLES
1-) A phase Ib study of the dual PI3K/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies Targeted oncology 12, 323-332, 2017
2-) Harnessing meta‐analysis to refine an oncology patient population for physiology‐based pharmacokinetic modeling of drugs Clinical Pharmacology & Therapeutics 103 (2), 271-280, 2018
3-) Phase ia/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors Clinical Cancer Research 28 (22), 4871-4884, 2022
4-) Abstract CT007: PETRA: first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations American Association for Cancer Research (AACR), 2022
5-) Evaluation of the drug–drug interaction potential of acalabrutinib and its active metabolite, ACP‐5862, using a physiologically‐based pharmacokinetic modeling approach CPT: pharmacometrics & systems pharmacology 8 (7), 489-499, 2019